Background: The aim of this study was to examine the cardiac effects of anthracycline therapy based on speckle-tracking echocardiography (STE) and to identify patients at risk for cardiotoxicity. Patients and Methods: The study included 35 breast cancer (BC) and 15 lymphoma patients who were treated with anthracycline-based chemotherapy. Conventional echocardiography and STE were performed 1 month prior to and 1 month after chemotherapy. Longitudinal strain analysis was performed via STE using automated functional imaging. Results: The ejection fraction (EF) and the fractional shortening values were significantly lower in the lymphoma group. There was a positive correlation between anthracycline dose and subclinical heart failure (p = 0.024). There was an increase in the myocardial performance index in both groups. After therapy, STE showed regional decreases in the longitudinal strain values in the BC group, but the global strain values did not differ. In the lymphoma group, the apical long-axis, the 4-chamber, and the global longitudinal strain values were significantly lower after therapy (p = 0.002, 0.041, and 0.004, respectively). The long-axis and global longitudinal strain values were significantly lower in the lymphoma patients with normal EF values (p = 0.01 and 0.05, respectively). Conclusion: Cardiotoxicity during the early phase of anthracycline treatment can be detected via STE prior to the observation of systolic function deterioration.

Keywords:
Anthracyclines, Cardiotoxicity, Speckle-tracking echocardiography, Breast cancer, Lymphoma
1.
Robert J, Gianni L: Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 1993;17:219-252.
2.
Ewer MS, Lippman SM: Type 2 chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900-2902.
3.
Elliott P: Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006;33:S2.
4.
Shan K, Linchoff MA, Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
5.
Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
6.
Arola OJ, Saraste A, Kallajoki M, Kallajoki M, Parvinen M, Voipio-Pulkki LM: Acute doxorubicine cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000;60:1789-1792.
7.
Hashimoto I, Li X, Hjmadi Bhat A, Jones M, Zetts AD, Sahn DJ: Myocardial strain rate is a superior method for evaluation of left ventricular subendocardial function compared with tissue Doppler imaging. J Am Coll Cardiol 2003;42:1574-1583.
8.
Sutherland GR, Di Salvo G, Claus P, D'hooge J, Bijnens B: Strain and strain rate imaging: a new clinical approach to quantifying regional myocardial function. J Am Soc Echocardiogr 2004;17:788-802.
9.
Bi XJ, Deng YB, Shentu WH: Assessment of left ventricular dyssynchrony in patients with hypertrophic cardiomyopathy by two-dimensional strain echocardiography. Chin J Med Imaging Technol (Chinese) 2008;24:1763-1766.
10.
De Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. 16 Lancet 2003;362:316-322.
11.
Sant M, Allemai C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R; EUROCARE Working Group: EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Result and commentary. Eur J Cancer 2009;45:931-991.
12.
Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin. A retrospective analysis of three trials. Cancer 2003;97:2869-2879.
13.
Zile MR, Baicu CF, Gaasch WH: Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350:1953-1959.
14.
Bristow MR, Mason JW, Billingham ME, Daniels JR: Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981;102:709-718.
15.
Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia J P, Oeffinger KC, Ritchey AK, Villaluna D, Relling M V, Bhatia S: Anthracycline related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes: a Children's Oncology Group study. J Clin Oncol 2012;30:1415-1421.
16.
Wildiers H, Jurcut R, Ganame J, Herbots L, Neven P, De Backer J, Denys H, Cocquyt V, Rademakers F, Voigt JU, Paridaens R: A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients. Crit Rev Oncol Hematol 2008;67:133-138.
17.
Al-Biltagi M, Abd Rab Elrasoul Tolba O, El-Shanshory MR, Abd El-Aziz El-Shitany N, El-Sayed El-Hawary E: Strain echocardiography in early detection of doxorubicin induced left ventricular dysfunction in children with acute lymphoblastic leukemia. ISRN Pediatr 2012;2012:870549.
18.
Piegari E, Di Salvo G, Castaldi B, Vitelli MR, Rodolico G, Golino P, Calabrò R, Rossi F, Berrino L: Myocardial strain analysis in a doxorubicin induced cardiomyopathy model. Ultrasound Med Biol 2008;34:370-378.
© 2013 S. Karger GmbH, Freiburg
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.